View Older Stories View More Recent Stories
-
Pre-Open Stock Movers 02/26: (ELX) (CYBX) (UIL) (CRM) Higher; (CLRX) (LKQ) (TASR) Lower (more...)
-
Landec to Present at the 27th Annual ROTH Conference on March 10, 2015
-
Profire Energy to Present at 27th Annual ROTH Conference on March 10, 2015
-
Lion Biotechnologies (LBIO) Prices 8M Common Offering at $8/Share
-
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
-
Celldex Therapeutics Prices Public Offering of Common Stock
-
Roth Tweaks Numbers on Auryxia Ahead of Keryx Pharna's (KERX) Q4 Report; Maintains 'Buy' Rating
-
Upcoming Milestones, Key Investment Points for Bio Blast Pharma (ORPN) Being Missed by Investors - Roth Capital
-
Curis (CRIS) Prices 21.8M Common Offering at $2.75/Share
-
Curis Prices Public Offering of Common Stock
-
Curis Reports Fourth Quarter and Year-End 2014 Financial Results
-
Revolution Lighting Technologies to Present at 27th Annual ROTH Conference
-
Notable Analyst Rating Changes 2/23: (LH) (PENN) (CL) Upgraded; (BA) (RIG) (DGX) Downgraded
-
Breakthrough Designation for Celldex's (CLDX) Rintega Points to Stronger FDA Support as Cancer Vaccine in GBM - Roth Capital
-
Roth Capital Upgrades New Gold (NGD) to Neutral
-
Roth Capital Starts Flex Pharma (FLKS) at Buy
-
Roth Capital Starts Zosano Pharma (ZSAN) at Buy
-
Roth Capital Downgrades Spectrum Pharmaceuticals (SPPI) to Neutral
-
Notable Analyst Rating Changes 2/20: (MRVL) (DSW) (KN) Upgraded; (FUEL) (HLSS) (REGN) Downgraded
-
Roth Capital Downgrades Regeneron (REGN) to Neutral; Pipeline Opportunities Largely Priced In
-
Notable Analyst Rating Changes 2/19: (COH) (VLO) (MWW) Upgraded; (I) (PCYC) (HUN) Downgraded
-
Pre-Open Stock Movers 02/19: (BJRI) (PCLN) (BBW) Higher; (OCRX) (NLST) (CSLT) Lower (more...)
-
UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
-
SolarCity (SCTY) May See N-T Weakness on Unfavorable Mix; Roth Maintains 'Buy' Rating
-
Roth Capital Starts Spark Therapeutics (ONCE) at Buy
-
ZAGG Inc to Present at 27th Annual Roth Conference
-
Hill International to Present at the 27th Annual ROTH Conference
-
Roth Capital Boosts Ests on Enphase (ENPH) Following Q4 Numbers, Outlook
-
Roth Affirms Bio Blast Pharma (ORPN) at 'Buy'; Plenty of Catalysts Ahead in Next 12 - 18 Months
-
Roth Still Positive on Cytori (CYTX) as ACT-OA Phase 2 Commences
-
Edgewater to Present at the 27th Annual ROTH Conference on March 10, 2015
-
Palatin (PTN) Outpaces Q2 Ests on BMT Program Milestone; Roth Capital Affirms at 'Buy'
-
Eco-Stim Energy Solutions Announces Pricing of Public Offering of Common Stock
-
Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
-
ImmunoCellular Therapeutics (IMUC) Prices Stock and Warrants Offeirng
-
ImmunoCellular Therapeutics (IMUC) Prices 26.65M Common, 18.66M Warrants Offering
-
Ohr Pharmaceutical (OHRP) Closes 4.26M Common Offering; Gross Proceeds at ~$28.8M
-
Streetinsider.com's Hot Lunchtime Reads 2/11: (AAPL) (OC) (IMMR) (FB)
-
2015 Expected to be 'Transformative' Year for Applied Genetic Technologies (AGTC) - Roth Capital
-
Notable Analyst Rating Changes 2/11: (NUS) (NSP) (YELP) Upgraded; (WMT) (XLS) (ATEN) Downgraded
-
Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
-
Delcath Systems (DCTH) Prices 2.46M Common Offering at $1.15/Share
-
Roth Capital Upgrades Insperity (NSP) to Buy
-
Delcath Systems (DCTH) to Offer Common Stock And Warrants
-
RedHill Biopharma (RDHL) Prices 1M Offering at $12.50/ADS
-
Roth Capital Starts CECO Environmental (CECE) at Neutral
-
RedHill Biopharma (RDHL) Reports Proposed Public Offering of ADS
-
Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced Public Offering
-
Roth Capital Starts Vermillion (VRML) at Buy
-
Notable Analyst Rating Changes 2/6: (IMGN) (FBP) (WWE) Upgraded; (YELP) (P) (VIAB) Downgraded

